Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Crinetics Pharmaceuticals (CRNX) EBIT: 2017-2025

Historic EBIT for Crinetics Pharmaceuticals (CRNX) over the last 9 years, with Sep 2025 value amounting to -$142.6 million.

  • Crinetics Pharmaceuticals' EBIT fell 62.40% to -$142.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$477.8 million, marking a year-over-year decrease of 55.77%. This contributed to the annual value of -$338.9 million for FY2024, which is 52.22% down from last year.
  • As of Q3 2025, Crinetics Pharmaceuticals' EBIT stood at -$142.6 million, which was down 10.44% from -$129.1 million recorded in Q2 2025.
  • Crinetics Pharmaceuticals' EBIT's 5-year high stood at -$22.9 million during Q1 2021, with a 5-year trough of -$142.6 million in Q3 2025.
  • Its 3-year average for EBIT is -$85.9 million, with a median of -$82.8 million in 2024.
  • Data for Crinetics Pharmaceuticals' EBIT shows a maximum YoY plummeted of 82.28% (in 2022) over the last 5 years.
  • Quarterly analysis of 5 years shows Crinetics Pharmaceuticals' EBIT stood at -$26.1 million in 2021, then crashed by 82.28% to -$47.6 million in 2022, then slumped by 31.76% to -$62.7 million in 2023, then tumbled by 51.21% to -$94.7 million in 2024, then crashed by 62.40% to -$142.6 million in 2025.
  • Its last three reported values are -$142.6 million in Q3 2025, -$129.1 million for Q2 2025, and -$111.4 million during Q1 2025.